United Therapeutics (UTHR) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
26 Jun, 2026Opening remarks and agenda
The meeting was held virtually on the company's 30th anniversary, with introductions of key executives and board members present online.
The agenda and rules of conduct were made available on the virtual meeting website, with instructions for participation and technical contingencies.
Board and executive committee updates
All 12 director nominees were introduced for election to serve one-year terms until the next annual meeting.
Key board members and committee chairs were present, including the Lead Independent Director and Nominating and Governance Committee Chair.
Shareholder proposals
Four proposals were presented for voting: election of directors, advisory approval of executive compensation, approval of the 2026 Stock Incentive Plan, and ratification of the independent auditor.
The board recommended voting in favor of all nominees and proposals.
Latest events from United Therapeutics
- Strong clinical results and pipeline advances underpin ambitious growth targets through 2027.UTHR
Jefferies Global Healthcare Conference 20263 Jun 2026 - Major clinical advances and regulatory progress set the stage for robust growth and innovation.UTHR
RBC Capital Markets Global Healthcare Conference 202619 May 2026 - Ralinepag cut PAH clinical worsening risk by 55% with robust efficacy and tolerability.UTHR
Study result15 May 2026 - Q1 2026 revenues fell 2% to $781.5M as Tyvaso DPI and Orenitram grew; $1.5B buyback executed.UTHR
Q1 20266 May 2026 - Annual meeting covers director elections, pay, new equity plan, auditor, and strong ESG focus.UTHR
Proxy filing29 Apr 2026 - Virtual annual meeting to vote on directors, compensation, stock plan, and auditor ratification.UTHR
Proxy filing29 Apr 2026 - Breakthrough clinical results and innovative therapies drive growth and pipeline expansion.UTHR
Leerink Global Healthcare Conference 202626 Mar 2026 - Ralinepag and Tyvaso advances drive growth, with major opportunities in PAH, IPF, and xenotransplantation.UTHR
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - 2025 revenue reached $3.18B, with Tyvaso DPI and Orenitram fueling double-digit growth.UTHR
Q4 202525 Feb 2026